Dermata Therapeutics (DRMA) Stock Forecast, Price Target & Predictions
DRMA Stock Forecast
Dermata Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a 279.75% upside from DRMA’s last price of $1.58) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
DRMA Price Target
The average price target for Dermata Therapeutics (DRMA) is $6.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 279.75% upside from DRMA's last price of $1.58.
DRMA Analyst Ratings
According to 1 Wall Street analysts, Dermata Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DRMA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Dermata Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 21, 2024 | Anthony Vendetti | Maxim Group | $6.00 | $2.06 | 190.56% | 279.75% |
The latest Dermata Therapeutics stock forecast, released on Aug 21, 2024 by Anthony Vendetti from Maxim Group, set a price target of $6.00, which represents a 190.56% increase from the stock price at the time of the forecast ($2.06), and a 279.75% increase from DRMA last price ($1.58).
Dermata Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $6.00 | $6.00 | $6.00 |
| Last Closing Price | $1.58 | $1.58 | $1.58 |
| Upside/Downside | 279.75% | 279.75% | 279.75% |
In the current month, the average price target of Dermata Therapeutics stock is $6.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 279.75% increase as opposed to Dermata Therapeutics's last price of $1.58. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 21, 2024 | Maxim Group | Buy | Buy | Hold |
| Feb 07, 2022 | Maxim Group | - | Hold | Initialise |
Dermata Therapeutics's last stock rating was published by Maxim Group on Aug 21, 2024. The company gave DRMA a "Buy" rating, the same as its previous rate.
Dermata Therapeutics Financial Forecast
Dermata Therapeutics Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| # Analysts | - | - | - |
| Surprise % | - | - | - |
Dermata Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. DRMA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Dermata Therapeutics EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict DRMA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Dermata Therapeutics's previous annual EBITDA (undefined) of $NaN.
Dermata Therapeutics Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| Net Income | - | - | - |
| Avg Forecast | $-920.13K | $-1.79M | $-2.40M |
| High Forecast | $-920.13K | $-1.79M | $-2.40M |
| Low Forecast | $-920.13K | $-1.79M | $-2.40M |
| Surprise % | - | - | - |
Dermata Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DRMA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Dermata Therapeutics SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
Dermata Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to DRMA last annual SG&A of $NaN (undefined).
Dermata Therapeutics EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EPS | - | - | - |
| Avg Forecast | $-1.36 | $-2.64 | $-5.40 |
| High Forecast | $-1.36 | $-2.64 | $-5.40 |
| Low Forecast | $-1.36 | $-2.64 | $-5.40 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, Dermata Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DRMA previous annual EPS of $NaN (undefined).
Dermata Therapeutics Peer Comparison by Price Target
DRMA Forecast FAQ
Is Dermata Therapeutics a good buy?
Yes, according to 1 Wall Street analysts, Dermata Therapeutics (DRMA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of DRMA's total ratings.
What is DRMA's price target?
Dermata Therapeutics (DRMA) average price target is $6 with a range of $6 to $6, implying a 279.75% from its last price of $1.58. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Dermata Therapeutics stock go up soon?
According to Wall Street analysts' prediction for DRMA stock, the company can go up by 279.75% (from the last price of $1.58 to the average price target of $6), up by 279.75% based on the highest stock price target, and up by 279.75% based on the lowest stock price target.
Can Dermata Therapeutics stock reach $2?
DRMA's average twelve months analyst stock price target of $6 supports the claim that Dermata Therapeutics can reach $2 in the near future.
What is Dermata Therapeutics's current price target trend?
1 Wall Street analyst forecast a $6 price target for Dermata Therapeutics (DRMA) this month, up 279.75% from its last price of $1.58. Compared to the last 3 and 12 months, the average price target increased by 279.75% and increased by 279.75%, respectively.
What are Dermata Therapeutics's analysts' financial forecasts?
DRMA's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-5.104M (high $-5.104M, low $-5.104M), average SG&A $0 (high $0, low $0), and average EPS is $-9.4 (high $-9.4, low $-9.4).